Best Interests & Forced Sales, page-2

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 2 Last

Share
Profile

Follow
Tiamaria

1,235 Posts.

119

26/05/22

20:13

Post #: 61646677
Share

Originally posted by Taurean7: ↑

Although reluctant to begin another thread there is one important aspect of the ‘best interest of shareholders’ that deserves separate consideration.

With both on-market and off-market takeovers, any target shareholder is able to decide for themself whether accepting a bidder’s offer is in their own personal best interest. Compulsory acquisition of their holding does not apply unless and until the bidder has obtained a 90% interest.

By choosing a Scheme of Arrangement and supporting it, the ResApp BOD has indicated its belief that it is in a better position to determine what is in all shareholders’ best interests than those shareholders themselves.

Without going into the particularly insulting nature of that attitude it does mean that the BOD considers one of the other alternatives, in which shareholders are able to decide their own future in the Company, to not be superior. The Scheme is the best.

An argument that an offer price is justified solely because it is higher than recent market prices is both trivial and naïve, but in any case the same offer made on- or off-market would be just as applicable.

Why giving shareholders the choice of determining their future is not in their best interests is well beyond my powers of perception. A rationalisation of the BOD’s attitude should be contained in the Target’s Statement of the Scheme Booklet, which will be worth reading.

Meanwhile an Independent Expert has the task of both justifying an offer price that demonstrably is nowhere near real value, and the choice of a Scheme that concludes that it is in the best interests of shareholders to not be shareholders.

Considering the Company’s much-vaunted exciting potential growth, someone who can successfully mold logic to reach those conclusions would be wasting their unique talent if it were confined solely to the area of investment valuations.

Expand

Totally agree!
The fact that sp has been flowing from 11-11.5 is also very interesting.
The offer has put a cap on the top but interesting it hasn't dropped below 11.

It has been manipulated by the offer.
This would need to be considered by any independent experts report.

The independent experts report should also take into consideration as to the benefit of the the acquisition to the buyer.???

RAP Price at posting: 11.0¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 9 more messages in this thread...

First 2 Last

Add RAP (ASX) to my watchlist

Best Interests & Forced Sales, page-2

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News